GlaxoSmithKline was wrong to set higher prices for exports in order to control parallel imports, but the European Commission was wrong to ignore the drug giant's arguments for doing so, according to an Opinion from an advisor to Europe's highest court.
This entry was posted
on Thursday, July 9th, 2009 at 5:17 pm and is filed under CyberLaw.
You can follow any responses to this entry through the RSS 2.0 feed.
You can skip to the end and leave a response. Pinging is currently not allowed.
